GlassScriptPhysician profile
Ellen D Caswell
NPI 1487018420
$5,112.11
in general payments reported to CMS, 2019-2025
34 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $144 · 2021: $484 · 2022: $1,010 · 2023: $815 · 2024: $1,144 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987 · Long Term Medical Supply Or Device Loan: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.10 |
| Long Term Medical Supply Or Device Loan | $194.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $955.95 | 2021-2025 | |
| Abbott Laboratories | $712.95 | 2021-2025 | Freestyle Libre, Freestyle Copilot, Freestyle Insulinx |
| Xeris Pharmaceuticals, INC. | $630.11 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $541.82 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $463.12 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $369.89 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Dexcom, INC. | $233.90 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.56 | 2019-2021 | |
| Lifescan, INC. | $112.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $101.53 | 2019 | |
| Insulet Corporation | $77.50 | 2024-2025 | Omnipod |
| Abbvie INC. | $68.70 | 2020-2024 | Ubrelvy |
| Corcept Therapeutics | $68.26 | 2023-2025 | Korlym |
| Medtronic, INC. | $65.90 | 2021-2025 | Minimed 780g |
| Grt US Holding, INC. | $64.63 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $61.75 | 2024-2025 | |
| Radius Health, INC. | $52.62 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $52.48 | 2020-2022 | |
| Eisai INC. | $47.11 | 2020 | |
| Sanofi-Aventis U.S. LLC | $34.49 | 2020-2024 | |
| Madrigal Pharmaceuticals | $32.54 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $29.97 | 2025 | Strensiq |
| Pfizer INC. | $27.73 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Recordati_rare_diseases_inc. | $23.07 | 2024 | Signifor Lar, Isturisa |
| Amphastar Pharmaceuticals, INC. | $19.72 | 2024 | Baqsimi |
| Beta Bionics, INC. | $19.04 | 2024 | Ilet Bionic Pancreas |
| Tandem Diabetes Care, INC. | $17.42 | 2021 | |
| Shire North American Group INC | $15.24 | 2019 | |
| Kyowa Kirin, INC. | $15.12 | 2023 | Crysvita |
| Zealand Pharma US, INC. | $14.40 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.66 | 2024 | Unithroid |
| Ucb, INC. | $12.87 | 2022 | |
| Merck Sharp & Dohme LLC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Caswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.